Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSCA-CAR T Cells for PSCA+ Metastatic Castration Resistant Prostate Cancer
NCT03873805Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Aug 2019
- Primary completion
- Aug 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PSCA CAR T cells in castration-resistant prostate cancer (CRPC), sponsored by City of Hope. Primary endpoints: Grade 3 Toxicity Profile at 32 months and Number of Participants Experiencing a Dose-limiting Toxicity at 28 days. Started Aug 2019; status: active, not recruiting.
02
Drugs
PSCA CAR T cells
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03873805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873805.